Items tagged with Drug-resistant TB

Beyond expectations: study finds treatment success gap in drug-resistant TB (post)

In a recent study published in the Journal of Infection, researchers performed a systematic literature review of global treatment outcomes of extensively drug-resistant Tuberculosis.

Proteomics reveals potential targets for drug-resistant TB (post)

TOPLINE:

Down-regulation of plasma exosome-derived apolipoproteins APOA1, APOB, and APOC1 indicates DR-TB status and lipid metabolism regulation in pathogenesis. 

Molecular insights may inform new treatments for drug-resistant TB (post)

In the face of growing antibiotic resistance among bacterial infections, scientists at The Hospital for Sick Children (SickKids) have delved into the molecular science behind treatment-resistant tuberculosis.

Kenya steps up its war against drug-resistant TB (post)

It started in early 2022, with a feeling of general body weakness and sickness, then came the weight loss, fever and night sweats that alarmed Laura Amollo. Several visits to health centres in the Eastlands area of Nairobi left both patient and health workers puzzled.

RESIST-TB July 2023 newsletter (post)

RESIST-TB released its July 2023 newsletter with the latest updates and research publications on drug-resistant TB.

Study demonstrates efficacy of new short-term resistant TB treatment (post)

Tuberculosis (TB) disproportionately affects vulnerable populations including those with limited economic resources, HIV patients, those whose diet is deficient in nutrients and others. Resistant TB (MDR TB) does not respond to first line medications and is difficult to treat, requiring long regimens of 15-20 months that are associated with significant side effects and poor outcomes.

WHO issues rapid communication on use of targeted next-generation sequencing for diagnosis of drug-resistant TB (post)

25 July 2023 | Geneva --Targeted next generation sequencing (NGS) for the detection of drug-resistant TB is a new class of diagnostic technology. It provides an option for rapid and accurate genetic analysis and detection of mutations associated with resistance in a fraction of the time required for culture-based methods for detecting resistance. Various commercially available “End-to-End” tests for targeted NGS have become available in recent years that can detect resistance to multiple drugs simultaneously, provide rapid results with testing directly on patient samples, and have the potential to assimilate new information on genetic markers for resistance as they become known.

RESIST-TB August 2023 newsletter (post)

RESIST-TB released its August 2023 newsletter with the latest updates and research publications on drug-resistant TB.

TB Alliance announces partnership with Remington Pharmaceuticals to commercialize new therapy for drug-resistant forms of TB in Pakistan (post)

NEW YORK (August 10, 2023)—Non-profit drug developer TB Alliance has granted Remington Pharmaceutical Industries (Pvt.) Ltd. a non-royalty bearing license to market the anti-tuberculosis (TB) medicine pretomanid as part of the all-oral, six-month BPaL and BPaLM regimens for treatment of drug-resistant TB (comprised of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin). Pakistan ranks third among countries designated by the World Health Organization as having a high burden of drug-resistant TB. Remington has agreed to develop, manufacture, and commercialize pretomanid in Pakistan and the collaboration may extend to other countries in the future.

Community perspective on child-friendly medications for drug-resistant TB: importance, priorities and advocacy (post)

An editorial, published in the International Journal of Tuberculosis and Lung Disease, elaborates on the need to advance child-friendly medications to treat pediatric drug-resistant TB.